Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab

被引：1

作者：

Chiang, Ryan S. ^{[1
]}

Glover, Michael J. ^{[1
]}

Khaki, Ali Raza ^{[2
]}

Srinivas, Sandy ^{[2
,3
]}

机构：

[1] Stanford Univ, Dept Med, Stanford, CA USA

[2] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA

[3] Stanford Univ, Dept Med, Div Oncol, 875 Blake Wilbur Dr,Clin E, Stanford, CA 94305 USA

来源：

ONCOTARGETS AND THERAPY | 2022年 / 15卷

关键词：

immune checkpoint inhibitors; immunotherapy; nivolumab; urothelial carcinoma; bladder cancer; INVASIVE BLADDER-CANCER; OPEN-LABEL; SINGLE-ARM; NEOADJUVANT CHEMOTHERAPY; MULTICENTER; ATEZOLIZUMAB; PEMBROLIZUMAB; CISPLATIN; THERAPY; METHOTREXATE;

D O I：

10.2147/OTT.S369043

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Over the past decade, the emergence of immune checkpoint inhibitors has brought about significant change to the treatment landscape of bladder cancer. Nivolumab is an immune checkpoint inhibitor that has shown favorable results resulting in FDA approval for treatment of platinum-refractory locally advanced or metastatic urothelial carcinoma. More recently, it was the first (and only) immune checkpoint inhibitor to receive FDA approval for the treatment of urothelial carcinoma in the adjuvant setting after radical surgery. Multiple trials are now actively underway to further understand the nuances in which immune checkpoint inhibitors such as nivolumab can be beneficial. In this review, we explore the development of nivolumab in terms of its mechanism of action, its growing indications in the treatment of urothelial carcinoma, and potential future directions for clinical trials. Immune checkpoint inhibitors are a promising treatment for bladder cancer, but further work is needed to continue to improve outcomes for patients.

引用

页码：1259 / 1269

页数：11

共 61 条

[1] Neoadjuvant chemotherapy in invasive bladder cancer:: Update of a systematic review and meta-analysis of individual patient data [J].

Abol-Enein, H ;

Bassi, P ;

Boyer, M ;

Coppin, CML ;

Cortesi, E ;

Grossman, HB ;

Hall, RR ;

Horwich, A ;

Malmström, PU ;

Martinez-Piñeiro, JA ;

Sengelov, L ;

Sherif, A ;

Wallace, DMA ;

Bono, AV ;

Goebell, PJ ;

Groshen, S ;

Torti, FM ;

Clarke, NW ;

Roberts, JT ;

Sylvester, R ;

Parmar, MKB ;

Stewart, LA ;

Tierney, JF ;

Vale, CL .

EUROPEAN UROLOGY, 2005, 48 (02) :202-206

[2] Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis [J].

Apolo, Andrea B. ;

Ellerton, John A. ;

Infante, Jeffrey R. ;

Agrawal, Manish ;

Gordon, Michael S. ;

Aljumaily, Raid ;

Gourdin, Theodore ;

Dirix, Luc ;

Lee, Keun-Wook ;

Taylor, Matthew H. ;

Schoeffski, Patrick ;

Wang, Ding ;

Ravaud, Alain ;

Manitz, Juliane ;

Pennock, Gregory ;

Ruisi, Mary ;

Gulley, James L. ;

Patel, Manish R. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[3] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].

Bajorin, D. F. ;

Witjes, J. A. ;

Gschwend, J. E. ;

Schenker, M. ;

Valderrama, B. P. ;

Tomita, Y. ;

Bamias, A. ;

Lebret, T. ;

Shariat, S. F. ;

Park, S. H. ;

Ye, D. ;

Agerbaek, M. ;

Enting, D. ;

McDermott, R. ;

Gajate, P. ;

Peer, A. ;

Milowsky, M., I ;

Nosov, A. ;

Antonio Jr, J. N. ;

Tupikowski, K. ;

Toms, L. ;

Fischer, B. S. ;

Qureshi, A. ;

Collette, S. ;

Unsal-Kacmaz, K. ;

Broughton, E. ;

Zardavas, D. ;

Koon, H. B. ;

Galsky, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114

[4] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study [J].

Balar, Arjun, V ;

Kamat, Ashish M. ;

Kulkarni, Girish S. ;

Uchio, Edward M. ;

Boormans, Joost L. ;

Roumiguie, Mathieu ;

Krieger, Laurence E. M. ;

Singer, Eric A. ;

Bajorin, Dean F. ;

Grivas, Petros ;

Seo, Ho Kyung ;

Nishiyama, Hiroyuki ;

Konety, Badrinath R. ;

Li, Haojie ;

Nam, Kijoeng ;

Kapadia, Ekta ;

Frenkl, Tara ;

de Wit, Ronald .

LANCET ONCOLOGY, 2021, 22 (07) :919-930

[5] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[6]

Baudino Troy A, 2015, Curr Drug Discov Technol, V12, P3

[7] The Wild West of Checkpoint Inhibitor Development [J].

Beaver, Julia A. ;

Pazdur, Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (14) :1297-1301

[8] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[9] Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial [J].

Bellmunt, Joaquim ;

Hussain, Maha ;

Gschwend, Jurgen E. ;

Albers, Peter ;

Oudard, Stephane ;

Castellano, Daniel ;

Daneshmand, Siamak ;

Nishiyama, Hiroyuki ;

Majchrowicz, Martin ;

Degaonkar, Viraj ;

Shi, Yi ;

Mariathasan, Sanjeev ;

Grivas, Petros ;

Drakaki, Alexandra ;

O'Donnell, Peter H. ;

Rosenberg, Jonathan E. ;

Geynisman, Daniel M. ;

Petrylak, Daniel P. ;

Hoffman-Censits, Jean ;

Bedke, Jens ;

Kalebasty, Arash Rezazadeh ;

Zakharia, Yousef ;

van der Heijden, Michiel S. ;

Sternberg, Cora N. ;

Davarpanah, Nicole N. ;

Powles, Thomas .

LANCET ONCOLOGY, 2021, 22 (04) :525-537

[10] Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art [J].

Califano, Gianluigi ;

Ouzaid, Idir ;

Laine-Caroff, Paul ;

Peyrottes, Arthur ;

Colla Ruvolo, Claudia ;

Pradere, Benjamin ;

Elalouf, Vincent ;

Misrai, Vincent ;

Hermieu, Jean-Francois ;

Shariat, Shahrokh F. ;

Xylinas, Evanguelos .

CURRENT ONCOLOGY, 2022, 29 (02) :687-697

← 1 2 3 4 5 6 7 →